Imeka is currently the only company to combine diffusion imaging and AI to map white matter integrity and get insights on neuroinflammation, demyelination and axonal loss. Therefore, with our non-invasive technology, we minimize risks for our pharma and biotech clients in the development of treatments for neurodegenerative diseases. Imeka’s main goal is to play an influential role in the search and development of cures for brain disease. Imeka’s diffusion imaging tools are able to measure extracellular water fraction (free-water), which is sensitive neuroinflammation. The technology pioneered by Imeka enhances white matter imaging and has applications in important brain disease areas such as Multiple Sclerosis, Alzheimer and Parkinson.